Maxim Group initiated coverage on shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) in a report issued on Thursday, April 20th. The brokerage issued a buy rating and a $135.00 price target on the biopharmaceutical company’s stock.
“Epilepsy remains a challenging indication to treat, with over a third of patients (750k patients in the U.S.) who are inadequately controlled despite several antiepileptic drugs (market of $5B) taken concurrently. GW’s lead product, Epidiolex, an orphan drug designated oral CBD (cannabidiol), showed positive results in three P3 trials for Dravet (DS) and Lennox-Gastaut syndromes (LGS).”,” Maxim Group’s analyst commented.
A number of other brokerages also recently weighed in on GWPH. Goldman Sachs Group Inc reiterated a buy rating and issued a $185.00 price target on shares of GW Pharmaceuticals PLC- in a report on Wednesday, February 22nd. TheStreet upgraded GW Pharmaceuticals PLC- from a d+ rating to a c- rating in a report on